Ioannis Kanakis

Prof. Ioannis Kanakis

Chester Medical School, University of Chester, Chester, Cheshire West and Chester, UK
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2009 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
KZKostantinos Zarogoulidis
Kostantinos Zarogoulidis
EBEufimia Boutsikou
Eufimia Boutsikou
Paul ZarogoulidisPaul Zarogoulidis
Paul Zarogoulidis
EEEllada Eleftheriadou
Ellada Eleftheriadou
TKTheodore Kontakiotis
Theodore Kontakiotis
Nikos KaramanosNikos Karamanos
Nikos Karamanos
Bone metastases occur in 20–40% of patients with lung cancer. Recent studies demonstrate a direct antiproliferative effect of 3rd generation bisphosphonates (BPs) on lung tumors, which may influence the survival. Therefore, we examined the clinical impact of zoledronic acid (ZOL; Zometa®), a 3rd generation BP, with a focus on the survival, time to progression and pain effect in lung cancer patients with bone metastases. Lung cancer patients (n = 144, Stage IV) with evidence of metastasis bone scan were included. Eighty‐seven of 144 experienced bone pain and received ZOL, 4 mg i.v. every 21 days (Group A), whereas the other 57 patients received no ZOL (Group B). All patients were treated with a combination chemotherapy consisted of docetaxel 100 mg/m2 and carboplatin AUC = 6. It was found that Group A had a statistically significant longer survival (p < 0.01) when compared to Group B. A statistically significant positive correlation was found between the number of cycles of therapy with ZOL and total patient survival (p < 0.01, Pearson correlation) and time to progression (p < 0.01). Pain effect of ZOL had no significant difference between the 2 groups of patients (p > 0.05). Urine N‐telopeptide of type I collagen (NTx) levels decreased in patients with NTx ≤ 29 nM BCE/mM creatinine at baseline after treatment with ZOL. The results of our study suggest that the addition of ZOL increases overall survival in lung cancer patients with bone metastases. The longer period of receiving ZOL, the better effect on survival and time to progression. © 2009 UICC

1 November 2006 in Journal of Biological Chemistry
Verified
Journal Article
Open access
ATAchilleas D. Theocharis
Achilleas D. Theocharis
CSCarina Seidel
Carina Seidel
Magne BørsetMagne Børset
Magne Børset
KDKatalin Dobra
Katalin Dobra
VBVadim Baykov
Vadim Baykov
AHAnders Hjerpe
Anders Hjerpe
Although the biological significance of proteoglycans (PGs) has previously been highlighted in multiple myeloma (MM), little is known about serglycin, which is a hematopoietic cell granule PG. In this study, we describe the expression and highly constitutive secretion of serglycin in several MM cell lines. Serglycin messenger RNA was detected in six MM cell lines. PGs were purified from conditioned medium of four MM cell lines, and serglycin substituted with 4-sulfated chondroitin sulfate was identified as the predominant PG. Flow cytometry and confocal microscopy showed that serglycin was also present intracellularly and on the cell surface, and attachment to the cell surface was at least in part dependent on intact glycosaminoglycan side chains. Immunohistochemical staining of bone marrow biopsies showed the presence of serglycin both in benign and malignant plasma cells. Immunoblotting in bone marrow aspirates from a limited number of patients with newly diagnosed MM revealed highly increased levels of serglycin in 30% of the cases. Serglycin isolated from myeloma plasma cells was found to influence the bone mineralization process through inhibition of the crystal growth rate of hydroxyapatite. This rate reduction was attributed to adsorption and further blocking of the active growth sites on the crystal surface. The apparent order of the crystallization reaction was found to be n=2, suggesting a surface diffusion-controlled spiral growth mechanism. Our findings suggest that serglycin release is a constitutive process, which may be of fundamental biological importance in the study of MM.

1 December 2012 in Biochimica et Biophysica Acta (BBA) - General Subjects
Verified
Journal Article
Closed access
PDP.G. Dedes
P.G. Dedes
CGCh. Gialeli
Ch. Gialeli
ATA.I. Tsonis
A.I. Tsonis
Ioannis KanakisIoannis Kanakis
Ioannis Kanakis
ATAchilleas D. Theocharis
Achilleas D. Theocharis
Nikos KaramanosNikos Karamanos
Nikos Karamanos

23 August 2007 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
XSXanthi N. Stahtea
Xanthi N. Stahtea
ARAndeas E. Roussidis
Andeas E. Roussidis
Ioannis KanakisIoannis Kanakis
Ioannis Kanakis
George TzanakakisGeorge Tzanakakis
George Tzanakakis
GCGeorge Chalkiadakis
George Chalkiadakis
Nikos KaramanosNikos Karamanos
Nikos Karamanos
Tumor progress depends on the proliferation of cancer cells, their interactions with stroma and the proteolytic action of enzymes. Colon cancer is c‐kit positive and responsive to the specific tyrosine kinase inhibitor imatinib. We investigated the effect of imatinib on the proliferation of a panel of epithelial colon cancer cell lines in presence and absence of the antimetabolite 5‐FU, and the effect of conditioned media (CM) derived from colon stromal fibroblasts with and without previous exposure to imatinib. The effects of imatinib on gene expression of MMPs and TIMPs were also studied. Imatinib effectively inhibited the proliferation of all cell lines, showing IC50 from 0.3 to 3 μM. Its combination with 5‐FU significantly enhances the growth inhibition of the highly tumourigenic HT‐29 cells. CM derived from stromal fibroblasts induced the proliferation of the HT‐29 cells; this stimulatory effect was abolished upon treatment with CM obtained after exposure of fibroblasts to imatinib. Gene expression of MT1‐, MT2‐MMP and MMP‐7 was also inhibited depending on the cell line, whereas that of TIMP‐2 was not affected. CM stimulated MT1‐MMP protein expression by HT‐29; this stimulatory effect was suppressed in the presence of imatinib. Activation of pro‐MMP2 to MMP2 in culture medium of HT‐29 treated with CM was increased and this activity was inhibited in presence of imatinib. The obtained data showed that imatinib is a powerful inhibitor of human colon cancer cell growth and effectively suppresses the stromal‐induced stimulation of cancer cell growth and activation of proMMP2. Further studies are warranted to evaluate the in vivo effects.

10 November 2012 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
DKD. E. Karangelis
D. E. Karangelis
Ioannis KanakisIoannis Kanakis
Ioannis Kanakis
AAA. P. Asimakopoulou
A. P. Asimakopoulou
EKE. Karousou
E. Karousou
Alberto PassiAlberto Passi
Alberto Passi
Nikos KaramanosNikos Karamanos
Nikos Karamanos
Cardiovascular disease is the largest cause of death in Western societies and it primarily results from atherosclerosis of large and medium-sized vessels. Atherosclerosis leads to myocardial infarction, when it occurs in the coronary arteries, or stroke, when it occurs in the cerebral arteries. Pathological processes involved in macrovascular disease include the accumulation of lipids which are retained by extracellular matrix (ECM) molecules, especially by the chondroitin sulfate/dermatan sulfate (CS/DS) proteoglycans (CS/DSPGs), such as versican, biglycan and decorin. The sulfation pattern of CS is a key player in protein interactions causing atherosclerosis. Several studies have shown that lipoproteins bind CSPGs via their glycosaminoglycan chains. Galactosaminoglycans, such as CS and DS, bind low density lipoproteins (LDL), affecting the role of these molecules in the arterial wall. In this article, the role of CS and versican in atherosclerosis and hyaluronan in atherogenesis as well as the up to date known mechanisms that provoke this pathological condition are presented and discussed.

1 March 2004 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
Ioannis KanakisIoannis Kanakis
Ioannis Kanakis
MNM. Nikolaou
M. Nikolaou
DPD. Pectasides
D. Pectasides
CKC. Kiamouris
C. Kiamouris
Nikos KaramanosNikos Karamanos
Nikos Karamanos